Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila...
https://pubmed.ncbi.nlm.nih.gov/28336552/Actively Recruiting
Led by Tempus AI · Updated on 2026-02-05
1200
Participants Needed
58
Research Sites
N/A
Total Duration
Researchers are studying patients with non-small cell lung cancer NSCLC to better understand how the cancer changes on a molecular level during standard treatments. The study aims to track the diseases progress and explore how changes in circulating tumor DNA ctDNA might predict cancer recurrence and treatment outcomes. This observational study collects clinical and molecular health data over time from patients receiving usual care. The study involves two groups of patients. The first group includes patients with early-stage NSCLC Stages I to IIIB who are treated with surgery and possibly additional therapies before or after surgery. The second group includes patients with advanced stage IV NSCLC receiving first-line immunotherapy, either alone or combined with chemotherapy. Patients will provide blood samples regularly during their routine care to help researchers analyze ctDNA and its changes over time. Participants will be asked to provide tumor samples and give additional blood samples during standard surveillance visits. Researchers will monitor disease-free survival and overall survival over periods up to five years. They will also compare ctDNA testing results with traditional imaging methods used every six months to detect cancer recurrence. The study tracks various outcomes, including treatment patterns and progression-free survival, to gain a detailed understanding of how the disease evolves under standard care.
CONDITIONS
GEMINI-NSCLC: NSCLC Biomarker Study
G
GEMINI NSCLC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tempus AI
Lead Sponsor
AstraZeneca
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed with additional blood samples collected during routine surveillance visits.
Visits approximately every 6 months for imaging and blood sample collection
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila...
https://pubmed.ncbi.nlm.nih.gov/28336552/Manabu Soda, Young Lim Choi, Munehiro Enomoto...
https://pubmed.ncbi.nlm.nih.gov/17625570/Giulia Siravegna, Silvia Marsoni, Salvatore Siena...
https://pubmed.ncbi.nlm.nih.gov/28252003/Puregmaa Khongorzul, Cai Jia Ling, Farhan Ullah Khan...
https://pubmed.ncbi.nlm.nih.gov/31659006/Enriqueta Felip, Nasser Altorki, Caicun Zhou...
https://pubmed.ncbi.nlm.nih.gov/34555333/Aparna R Parikh, Emily E Van Seventer, Giulia Siravegna...
https://pubmed.ncbi.nlm.nih.gov/33926918/Thomas Reinert, Tenna Vesterman Henriksen, Emil Christensen...
https://pubmed.ncbi.nlm.nih.gov/31070691/Robert Brody, Yiduo Zhang, Marc Ballas...
https://pubmed.ncbi.nlm.nih.gov/29191596/Urania Dafni, Zoi Tsourti, Katerina Vervita...
https://pubmed.ncbi.nlm.nih.gov/31319971/Benjamin J Solomon, Tony Mok, Dong-Wan Kim...
https://pubmed.ncbi.nlm.nih.gov/25470694/Tempus AI
Lead Sponsor
AstraZeneca
Collaborating Sponsor